TEST DIRECTORY

AND OR

TOP
endocrinology test
endocrinological test (others)

Laboratory：Hachioji

○endocrinological test (others)

TEST NAME	SPECIMEN REQUIREMENT （ｍL）	CONTAINER	CAP COLOR	STORE TEMPERATURE (STABILITY)	TURNAROUND TIME (DAY)	METHODOLOGY	REFERENCE RANGE (UNIT)
Plasma renin activity (PRA)（Suspended beyond orders placed 03-31-2021）	plasma 0.3	PN2,PN5 ↓ A00		（1 month）	3-5	RIA2 antibody assay Radio immunoassay (RIA) A target antigen is labeled with radioactive isotope (RI) and bound to its specific antibodies which is then competitively reacted with an antigen in a specimen. After the antigen-antibody reaction, the bound labeled antigens (bound) are separated from the unbound ones (free), and the antigen concentration is determined based on the proportion of radioactivity. 　To separate the bound and free antigens (B/F separation), the following methods are used. Solid-phase method:Antibodies are linked to the solid phase. Double antibody method: Antigen-antibody complexes are bound to the second antibody and precipitated. Ammonium sulfate precipitation method: Antigen-antibody complexes are precipitated by ammonium sulfate. PEG method: Antigenantibody complexes are precipitated by a precipitation reagent.	Supine: 0.3-2.9 Upright: 0.3-5.4 (ng/mL/hr)
Renin quantitative, activity（Suspended beyond orders placed 03-31-2021）	plasma 0.5	PN2,PN5 ↓ A00		（20 days）	2-5	RIA solid phase method Immunoradiometric assay (IRMA) IRMA is one of the techniques of RIA. Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with antibodies labeled with radioactive isotope (RI). This is also called as the sandwich technique, because the solid-phase linked antibodies and the RI-labeled antibodies bind to the antigens, respectively, forming an antigen sandwich.	Other states: 3.2-36 Supine: 2.5-21 Upright: 3.6-64 (pg/mL)
Angiotensin I（Suspended beyond orders placed 03-31-2022）	plasma 0.2	PN2,PN5 ↓ A00			6-12	RIA2 antibody assay Radio immunoassay (RIA) A target antigen is labeled with radioactive isotope (RI) and bound to its specific antibodies which is then competitively reacted with an antigen in a specimen. After the antigen-antibody reaction, the bound labeled antigens (bound) are separated from the unbound ones (free), and the antigen concentration is determined based on the proportion of radioactivity. 　To separate the bound and free antigens (B/F separation), the following methods are used. Solid-phase method:Antibodies are linked to the solid phase. Double antibody method: Antigen-antibody complexes are bound to the second antibody and precipitated. Ammonium sulfate precipitation method: Antigen-antibody complexes are precipitated by ammonium sulfate. PEG method: Antigenantibody complexes are precipitated by a precipitation reagent.	≦ 110 (pg/mL)
Angiotensin II（Suspended beyond orders placed 03-31-2022）	plasma 0.3	PN2,PN5 ↓ A00			6-12	RIA2 antibody assay Radio immunoassay (RIA) A target antigen is labeled with radioactive isotope (RI) and bound to its specific antibodies which is then competitively reacted with an antigen in a specimen. After the antigen-antibody reaction, the bound labeled antigens (bound) are separated from the unbound ones (free), and the antigen concentration is determined based on the proportion of radioactivity. 　To separate the bound and free antigens (B/F separation), the following methods are used. Solid-phase method:Antibodies are linked to the solid phase. Double antibody method: Antigen-antibody complexes are bound to the second antibody and precipitated. Ammonium sulfate precipitation method: Antigen-antibody complexes are precipitated by ammonium sulfate. PEG method: Antigenantibody complexes are precipitated by a precipitation reagent.	≦ 22 (pg/mL)
Cyclic AMP	plasma 0.3	PN2,PN5 ↓ A00		（1 month）	Please contact us in advance.	RIA DCC method Radio immunoassay (RIA) A target antigen is labeled with radioactive isotope (RI) and bound to its specific antibodies which is then competitively reacted with an antigen in a specimen. After the antigen-antibody reaction, the bound labeled antigens (bound) are separated from the unbound ones (free), and the antigen concentration is determined based on the proportion of radioactivity. 　To separate the bound and free antigens (B/F separation), the following methods are used. Solid-phase method:Antibodies are linked to the solid phase. Double antibody method: Antigen-antibody complexes are bound to the second antibody and precipitated. Ammonium sulfate precipitation method: Antigen-antibody complexes are precipitated by ammonium sulfate. PEG method: Antigenantibody complexes are precipitated by a precipitation reagent.	11-21 (pmol/mL)
Cyclic AMP	urine collected for 24 hrs 1	U00			Please contact us in advance.	RIA DCC method Radio immunoassay (RIA) A target antigen is labeled with radioactive isotope (RI) and bound to its specific antibodies which is then competitively reacted with an antigen in a specimen. After the antigen-antibody reaction, the bound labeled antigens (bound) are separated from the unbound ones (free), and the antigen concentration is determined based on the proportion of radioactivity. 　To separate the bound and free antigens (B/F separation), the following methods are used. Solid-phase method:Antibodies are linked to the solid phase. Double antibody method: Antigen-antibody complexes are bound to the second antibody and precipitated. Ammonium sulfate precipitation method: Antigen-antibody complexes are precipitated by ammonium sulfate. PEG method: Antigenantibody complexes are precipitated by a precipitation reagent.	1.8-6.3 (μmol/day)
Human atrial natriuretic peptide (HANP)	plasma 0.5	PAP ↓ A00		（21 days）	2-4	CLEIA Chemiluminescent enzyme immunoassay (CLEIA) Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies. After adding a chemiluminescent substrate, the emission intensity is measured.	≦ 43.0 (pg/mL)
Human brain natriuretic peptide (BNP)	plasma 0.5	PN2,PN5 ↓ A00			2-4	CLEIA Chemiluminescent enzyme immunoassay (CLEIA) Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies. After adding a chemiluminescent substrate, the emission intensity is measured.	≦ 18.4 (pg/mL)
N-terminal fragment of human brain natriuretic peptide precursor (NTproBNP)	serum 0.4	S09 ↓ A00			2-4	ECLIA Electro chemiluminescence immunoassay (ECLIA) Antibody-bound beads are reacted with antigens that are secondarily reacted with antibodies labeled with rutheniumpyridine complexes, which promotes the electrochemical reaction. The emission intensity of ruthenium-pyridine complexes is measured.	≦ 125 (pg/mL)
Erythropoietin	serum 0.8	S09 ↓ A00		（28 days）	2-4	CLEIA Chemiluminescent enzyme immunoassay (CLEIA) Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies. After adding a chemiluminescent substrate, the emission intensity is measured.	4.2-23.7 (mIU/mL)
Osteocalcin	serum 0.3	S09 ↓ A00			2-4	ECLIA Electro chemiluminescence immunoassay (ECLIA) Antibody-bound beads are reacted with antigens that are secondarily reacted with antibodies labeled with rutheniumpyridine complexes, which promotes the electrochemical reaction. The emission intensity of ruthenium-pyridine complexes is measured.	Premenopausal women 7.8-30.8 Postmenopausal women 14.2-54.8 Male 8.4-33.1 (ng/mL)
Undercarboxylated osteocalcin (ucOC)	serum 0.5	S09 ↓ A00		（21 days）	2-4	ECLIA Electro chemiluminescence immunoassay (ECLIA) Antibody-bound beads are reacted with antigens that are secondarily reacted with antibodies labeled with rutheniumpyridine complexes, which promotes the electrochemical reaction. The emission intensity of ruthenium-pyridine complexes is measured.	< 4.50 (ng/mL)
Hepatocyte growth factor (HGF)	serum 0.3	S09 ↓ A00		（1 month）	2-8	ELISA Enzyme-linked immunosorbent assay (ELISA) Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies. After adding a chromogenic substrate, the enzyme activity is measured.	≦ 0.39 (ng/mL)
Fibroblast growth factor 23 (FGF23), CLEIA	serum 0.4	S09 ↓ A00		（21 days）	2-6	CLEIA	19.9-52.9 (pg/mL)
Adiponectin, LA	serum 0.5	S09 ↓ A00			2-4	Latex turbidimetric immunoassay	≧ 4.0 (μg/mL)
Fibroblast growth factor 23 (FGF-23)（Suspended beyond orders placed 03-31-2020）	serum 0.3	S09 ↓ A00		（14 days）	2-8	ELISA Enzyme-linked immunosorbent assay (ELISA) Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies. After adding a chromogenic substrate, the enzyme activity is measured.	16-69 (pg/mL)